In re: Nexium (Esomeprazole) Products Liability Litigation
Published: Nov. 8, 2014 | Result Date: Oct. 8, 2014 | Filing Date: Jan. 1, 1900 |Case number: 2:12-cv-02404-DSF-SS Bench Decision – Defense
Court
USDC Central
Attorneys
Plaintiff
Thomas V. Girardi
(Girardi & Keese)
Keith D. Griffin
(Girardi & Keese)
Lauren E.S. Horwitz
(Banafsheh, Danesh & Javid PC)
Defendant
Peter A. Strotz
(King & Spalding LLP)
Megan R. Nishikawa
(King & Spalding LLP)
Farley J. Neuman
(Goodman, Neuman & Hamilton LLP)
Facts
Plaintiffs filed a suit against several defendants, including AstraZeneca Pharmaceuticals LP, AstraZeneca LP, and McKesson Corp., concerning the drug, Nexium.
Contentions
PLAINTIFFS' CONTENTIONS:
Plaintiffs alleged that they ingested the drug, Nexium, which was manufactured, designed, and sold by defendants. Plaintiffs alleged that they suffered injuries as a result of ingesting Nexium. Plaintiffs' alleged injuries included, among others, osteoporosis and other bone problems. Plaintiffs alleged that defendants downplayed the health hazards and adverse effects associated with Nexium. Plaintiffs' asserted its position is consistent with the FDA who required AstraZeneca to add a warning about bone fractures to its label for Nexium in 2010.
Result
The court granted defendants' motion for summary judgment. Accordingly, it entered judgment in favor of defendants.
Other Information
Plaintiffs intend to appeal to the 9th Circuit Court of Appeals. FILING DATE: Dec. 10, 2012.
For reprint rights or to order a copy of your photo:
Email
jeremy@reprintpros.com
for prices.
Direct dial: 949-702-5390